Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
super NK cell
- Development stage
- Phase 1
- Lead developer
- Institute of Hematology and Blood Diseases Hospital
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
super NK cell is an induced pluripotent stem cell (iPSC)-derived natural killer (NK) cell therapy developed by the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences. It is being investigated for the treatment of relapsed or refractory acute myeloid leukemia (AML) and AML with minimal residual disease (MRD). As an iPSC-derived product, it is designed to be an "off-the-shelf" therapy, potentially overcoming the limitations of patient-specific or donor-derived NK cells regarding scalability and standardization. The "super" designation typically refers to optimized expansion protocols or genetic enhancements intended to improve the cytotoxicity, persistence, and tumor-infiltrating capabilities of the NK cells compared to conventional primary NK cells. In clinical settings, it is often evaluated alongside chimeric antigen receptor (CAR)-modified NK cells to establish a baseline for safety and efficacy in myeloid malignancies.
- Other names
- iPSC-derived NK celliPSC-NK cellsuper NK cell-Institute of Hematology & Blood Diseases Hospital
Beyond the preview
Go deeper on super NK cell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on super NK cell.